Retatrutide and the Future of Triple Agonists (GLP-1, GIP, Glucagon)

Written by Dan Cripe, RN, BSN & Marcia Cripe, RN | Last Updated: September 19, 2026

If you're already taking semaglutide or tirzepatide and keep hearing that an even more powerful obesity medication may be coming next, retatrutide is probably the name you're hearing. The attention around it is not simply the usual excitement surrounding a new GLP-1 drug.

Retatrutide does something different. Instead of targeting one hormone receptor like semaglutide or two like tirzepatide, it activates three: GLP-1, GIP and glucagon receptors.

The weight-loss results have been substantial. In the Phase 3 TRIUMPH-1 obesity trial, participants receiving the highest studied dose lost an average of 28.3% of their starting body weight at 80 weeks. Among participants with a baseline BMI of at least 35 who continued into a longer study extension, average weight loss reached 30.3% at 104 weeks.

Those numbers move medication-based obesity treatment into territory that would have sounded extraordinary only a few years ago. They also make it easy to jump ahead and start wondering whether retatrutide is something you should be trying to get now.

The most important fact comes first: retatrutide is still investigational and is not currently FDA approved. There is no legitimate FDA-approved retatrutide product available for a clinician to prescribe today, so the useful question right now is not how to obtain it early. It is what scientists changed, what the trials actually show and why adding a third hormone pathway may matter.

The Triple Mechanism: Adding Glucagon to the Mix

The easiest way to understand retatrutide is to look at the progression of modern incretin treatment. Semaglutide activates the GLP-1 receptor, tirzepatide activates GIP and GLP-1 receptors, and retatrutide activates GIP, GLP-1 and glucagon receptors.

That makes retatrutide a triple hormone receptor agonist. You may occasionally see it called a “GLP-3,” but that nickname is scientifically inaccurate because there is no third GLP receptor being added; retatrutide is acting on three different hormone-receptor systems.

GLP-1 signaling can reduce food intake and increase satiation while also influencing glucose-dependent insulin secretion and other metabolic processes. GIP adds another incretin pathway and is one of the important pharmacologic differences between tirzepatide and medications that activate GLP-1 alone.

Retatrutide then adds glucagon receptor agonism. That third pathway is particularly interesting because glucagon has metabolic effects that differ from GLP-1 and GIP, and researchers have investigated whether glucagon receptor activity can influence energy expenditure and fat metabolism while the other components help regulate food intake and glucose metabolism.

That does not mean scientists simply stacked three weight-loss hormones together and created three times the effect. These receptor systems interact with complicated metabolic pathways, and researchers are still determining how much each component contributes to the overall response.

Conceptually, however, retatrutide represents an important change in strategy. Obesity pharmacotherapy may increasingly be able to influence both sides of energy balance — how much energy you consume and how your body uses it — rather than relying predominantly on reducing energy intake.

Phase 2 and Phase 3 Trial Results and Weight Loss Percentages

Retatrutide first attracted enormous attention because of its Phase 2 obesity trial. The study enrolled 338 adults with obesity or overweight plus a weight-related condition who did not have diabetes and tested once-weekly doses ranging from 1 mg to 12 mg over 48 weeks.

The results showed a clear dose-response pattern:

The magnitude of the losses was impressive, but another feature of the trial generated just as much interest. At the higher doses, the weight-loss curves had not clearly plateaued when the 48-week study ended, suggesting participants might continue losing weight with longer treatment.

That raised an obvious scientific question: would those early results continue when retatrutide moved into larger and longer Phase 3 trials? The TRIUMPH program has now started answering that question.

TRIUMPH-1

TRIUMPH-1 studied adults with obesity or overweight plus at least one weight-related complication who did not have diabetes. At 80 weeks, average weight loss increased substantially across the studied retatrutide doses.

At the highest dose, participants lost an average of approximately 70 pounds, and 45.3% of those receiving 12 mg lost at least 30% of their starting body weight. That places a substantial portion of the treatment group into a range of weight reduction historically associated much more closely with metabolic surgery than with medication.

A prespecified extension provided an even longer view of treatment. Participants who entered the study with a BMI of at least 35 could continue, and those receiving 12 mg had lost an average of 30.3% of their starting body weight at 104 weeks, equivalent to approximately 85 pounds.

These numbers should not be turned into individual expectations. They are group averages from a defined clinical-trial population, and people within those groups experienced different amounts of weight loss.

What TRIUMPH-1 does show is that the large reductions first seen in Phase 2 persisted when retatrutide moved into a larger and longer pivotal trial. The efficacy signal did not disappear with more participants and longer follow-up.

Other Phase 3 populations matter too

Retatrutide has also been tested in populations whose metabolic circumstances can make weight reduction more complicated. Those trials help demonstrate why the largest percentage reported in one study should never become the expected outcome for everyone who eventually receives a medication.

In TRIUMPH-2, adults with overweight or obesity and type 2 diabetes lost an average of up to 20.8% at 80 weeks. TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, and average weight loss at the highest dose reached 22.6% at 80 weeks.

Those averages are lower than the 28.3% observed with the highest dose in TRIUMPH-1, but that difference is clinically informative. Diabetes status, cardiovascular disease, baseline metabolic health and other characteristics can influence the response to obesity treatment.

For you, the practical lesson is that there is no single “retatrutide weight-loss percentage.” Trial results need to be understood in the context of the population being treated rather than pulled from one study and applied universally.

Retatrutide vs. Tirzepatide Efficacy

This is where comparing headline numbers becomes extremely tempting. Retatrutide's Phase 3 averages are numerically larger than the averages reported in major tirzepatide obesity trials, but that does not establish that retatrutide is definitively more effective than tirzepatide.

The reason is that these results come from separate trials. The studies used different participant populations, treatment durations, protocols, eligibility criteria and statistical approaches.

A randomized head-to-head trial provides much stronger comparative evidence than placing the final percentage from one study next to the final percentage from another. You therefore cannot take a retatrutide result around 28% and a tirzepatide result in the 20-something-percent range and calculate that retatrutide is a particular percentage “better.”

What the separate clinical programs show is still important. Tirzepatide demonstrated that targeting GIP and GLP-1 together could produce very large average weight reductions, while retatrutide adds glucagon receptor activity and has now produced even larger numerical reductions in several trials.

The scientific question is whether that triple-receptor mechanism ultimately provides a clinically meaningful advantage over tirzepatide when the treatments are compared appropriately. It will also matter whether any advantage is consistent across populations or is more important for particular types of patients.

For you, the distinction matters because the medication with the largest headline number is not automatically the medication that would produce the largest benefit in your body. Comparative treatment decisions require comparative evidence.

Unique Side Effect Profile: Heart Rate, Rhythm and Other Safety Findings

Retatrutide's glucagon component is interesting because it may contribute to the medication's metabolic effects, but adding another receptor pathway also creates additional physiological effects that researchers need to understand.

One finding from the Phase 2 obesity trial was a dose-dependent increase in heart rate. Heart rate increased through approximately week 24 and then declined later during treatment, with investigators noting that the changes were similar to increases previously reported with GLP-1 receptor agonists.

Cardiac arrhythmias were also reported in Phase 2, although most were mild to moderate. One severe prolonged-QT event occurred in a participant who was also taking ondansetron, making it an important finding to document without proving that retatrutide routinely causes dangerous rhythm disturbances.

That distinction is exactly why later-stage safety data and regulatory review matter. Early trials identify possible signals and tell researchers what deserves additional attention; they do not necessarily establish the frequency or clinical importance of a risk in routine treatment.

If retatrutide is eventually approved, its prescribing information will reflect a much larger safety dataset than the Phase 2 trial alone. The ultimate cardiovascular safety picture therefore matters just as much as the weight-loss percentages attracting attention now.

The more common side effects look more familiar

Many of the most frequently reported adverse effects will look familiar to anyone who has used or researched semaglutide or tirzepatide. Gastrointestinal effects have included nausea, diarrhea, vomiting, constipation and decreased appetite, and these symptoms have generally occurred more often as the dose increased.

In Phase 2, gastrointestinal adverse events were usually mild to moderate, and beginning treatment at a lower dose reduced some of those effects. Phase 3 trials have continued to identify gastrointestinal symptoms as the most common adverse events.

Retatrutide has also produced at least one less familiar finding. Cutaneous hyperesthesia and other skin-sensitivity events occurred in about 7% of retatrutide-treated participants in Phase 2 compared with approximately 1% receiving placebo.

Those skin-sensitivity events were not severe or serious in that trial and did not cause participants to discontinue treatment. They nevertheless demonstrate why a new medication should not simply be assumed to have the exact same adverse-effect profile as the drug class that came before it.

The final clinical value of retatrutide will therefore depend on more than how much weight participants can lose. Efficacy has to be considered alongside long-term safety, tolerability and whether people can realistically remain on treatment.

Why 30% Weight Loss Changes the Conversation

For decades, there was an enormous gap between the amount of weight people could typically lose with medication and the amount achievable with metabolic or bariatric surgery. The modern incretin era has been steadily narrowing that gap, and retatrutide pushes the discussion further.

When meaningful numbers of trial participants begin losing 20%, 25% or even 30% of their starting body weight with medication, clinicians have to think beyond the traditional question of whether a weight-loss drug is effective. The conversation begins to include a different set of questions:

• How much weight loss is medically appropriate for this individual?
• At what point should active weight reduction stop and maintenance begin?
• How should protein intake, nutrition and lean mass be protected during very large losses?
• What happens to bone health during prolonged, substantial weight reduction?
• Does someone who responds strongly need to continue escalating to the highest available dose?
• What should long-term maintenance look like after losing 25% or 30% of starting body weight?
• How should treatment change when someone responds more strongly than expected?

Those questions matter because the goal of obesity treatment is not to make the number on the scale as small as possible. It is to improve health while protecting nutrition, muscle, physical function and long-term quality of life.

A medication capable of producing greater weight loss therefore makes individualized treatment more important, not less. Someone who reaches an appropriate clinical endpoint at a lower dose may have no reason to continue escalating simply because a higher dose produced a larger average result in a trial.

The era of highly effective obesity medications may eventually require clinicians to think as carefully about when to slow or stop active weight reduction as they currently think about how to produce it.

When Will Retatrutide Be FDA Approved?

As of September 2026, retatrutide is not FDA approved, although its development program has advanced substantially and multiple pivotal Phase 3 trials have produced positive results.

Those trials include TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 and TRIUMPH-4. Lilly announced in July 2026 that it believes it now has the clinical data package needed to support global regulatory submissions and plans to submit an application to FDA in the first quarter of 2027.

A planned regulatory submission is not an approval date. Once an application is filed, FDA still has to evaluate the complete evidence package, including efficacy, safety, manufacturing, product quality, labeling and other regulatory requirements.

FDA can approve an application, request additional information or take other regulatory action based on its review. There is therefore no responsible way to promise exactly when retatrutide will be available as an FDA-approved prescription medication.

This also matters when you encounter products already being sold online as “retatrutide,” “research retatrutide” or “retatrutide for research use only.” Those products are not FDA-approved retatrutide medications, and positive clinical-trial results do not establish that an online peptide is equivalent to the investigational drug manufactured and studied under controlled trial conditions.

Until regulatory review is completed, clinical-trial retatrutide and an online vial carrying the same name should not be treated as interchangeable products.

What Retatrutide Tells Us About the Future of Obesity Treatment

Retatrutide may eventually become another approved obesity medication, but its larger importance may be what it tells us about where metabolic drug development is heading.

Semaglutide showed what sustained GLP-1 receptor activation could accomplish. Tirzepatide added GIP receptor activity, while retatrutide adds glucagon receptor agonism to create a third distinct pharmacologic strategy.

Researchers are already investigating additional combinations of hormones and metabolic pathways. That suggests the future is unlikely to be simply a competition to manufacture an increasingly “strong” GLP-1 medication.

Instead, treatment development is moving toward identifying combinations of biological signals that can influence appetite, glucose regulation, energy expenditure, fat metabolism and obesity-related disease while remaining tolerable enough for long-term treatment.

For people living with obesity, that could ultimately be much more useful than having one progressively more powerful drug after another. People do not all respond to obesity medications in the same way, and a larger set of genuinely different mechanisms could eventually allow clinicians to match therapy more effectively to different biological patterns of disease and treatment response.

Retatrutide is particularly important because it tests whether adding another metabolic target can change both the magnitude and character of the response. Even if its final place in treatment turns out to be more complicated than the headline percentages suggest, the strategy itself is likely to influence what comes next.

What This Means for You Right Now

If semaglutide or tirzepatide is working well for you, retatrutide's trial results are not a reason to assume your current treatment has become obsolete. A medication that is helping you reach an appropriate health goal does not suddenly become inadequate because another drug produced a larger average result in a separate clinical trial.

If your current treatment is not producing the response you hoped for, retatrutide is also not yet an approved medication you can simply switch to. The evidence has moved well beyond a small experimental study, but the drug has not completed FDA review and there is no FDA-approved commercial retatrutide product available today.

For now, the most useful way to understand retatrutide is as a late-stage investigational triple-receptor medication showing what the next generation of obesity pharmacotherapy may be capable of. Its results are scientifically important, but clinical-trial success and regulatory approval are still two different milestones.

Both parts of the story matter. Retatrutide has produced remarkable average weight loss in clinical trials, and it remains an investigational medication awaiting regulatory review.

Sources

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526.
   https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
2. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026.
   https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025.
   https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
4. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
   https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
5. Eli Lilly and Company. What to know about retatrutide.
   https://www.lilly.com/news/stories/what-to-know-about-retatrutide